Core Viewpoint - Yibai Pharmaceutical (600594.SH) announced that it expects a negative net profit attributable to shareholders for the fiscal year 2025, indicating an anticipated operational loss for the company in that year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1]

Core Viewpoint - Yibai Pharmaceutical (600594.SH) is expected to report a negative net profit attributable to shareholders for the fiscal year 2025, indicating an operational loss for the company [1] Financial Performance - The company’s financial department has conducted preliminary calculations, forecasting a loss for the fiscal year 2025 [1] - Yibai Pharmaceutical will adhere to the regulations set forth by the Shanghai Stock Exchange and expedite its financial accounting processes [1] - The final financial data will be based on the officially disclosed audited annual report for 2025 [1]

Core Viewpoint - Yibai Pharmaceutical (600594) announced that it expects a negative net profit for the fiscal year 2025, indicating an anticipated operational loss for the year [1] Financial Performance - The company’s financial department has conducted preliminary calculations, leading to the expectation of a loss in 2025 [1] - Yibai Pharmaceutical will adhere to the Shanghai Stock Exchange listing rules and expedite its financial accounting process [1] Future Disclosure - The company commits to disclosing the 2025 annual performance forecast within the stipulated timeframe [1] - The final financial data will be based on the officially disclosed audited annual report for 2025 [1]

Financial Performance Expectations - Guizhou Yibai Pharmaceutical Co., Ltd. expects a net profit attributable to shareholders to be negative for the fiscal year 2025, indicating an anticipated loss[1] - Final financial data will be based on the officially disclosed audited annual report for 2025[1] Compliance and Reporting - The company is accelerating its financial accounting processes to comply with the Shanghai Stock Exchange regulations and will disclose the 2025 performance forecast within the stipulated timeframe[1]

Core Insights - The article highlights that as of January 9, a total of 146 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is ST Renfu, which has seen net purchases for 12 consecutive trading days [1] - Other notable stocks with significant net buying days include *ST Yedao, Yibai Pharmaceutical, Fenglong Co., Ningbo United, Xingdesheng, Zhongchen Technology, Jinzong Co., and Funeng Co. [1] Summary by Category - **Market Activity** - A total of 146 stocks have recorded net buying from major funds for five days or more [1] - ST Renfu leads with 12 consecutive days of net buying [1] - **Notable Stocks** - Other stocks with considerable net buying include *ST Yedao, Yibai Pharmaceutical, Fenglong Co., Ningbo United, Xingdesheng, Zhongchen Technology, Jinzong Co., and Funeng Co. [1]

Core Viewpoint - As of January 7, a total of 137 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Huaneng Hydropower, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Meike Home, Aiko Photonics, ST Renfu, Yibai Pharmaceutical, Fenglong Co., ST Huapeng, Fuanna, and Yuanxin Industrial [1]

Core Insights - The 2025 Guizhou Top 100 Private Enterprises and Top 20 Private Manufacturing Enterprises were announced, showcasing the resilience and vitality of the private economy in Guizhou, which is becoming a significant force for high-quality development in the province [2][11]. Group 1: Rankings and Performance - The threshold for entering the 2025 Guizhou Top 100 Private Enterprises is set at 693 million yuan, an increase of 51 million yuan or 7.94% from the previous year [11]. - The total revenue of the top 100 enterprises reached 294.69 billion yuan, an increase of 7.96 billion yuan or 2.78% year-on-year [11]. - The manufacturing sector remains dominant, comprising over 60% of the top 100 enterprises, with 62 companies in this category [11]. Group 2: Characteristics of Top Enterprises - The top 100 enterprises exhibit five key characteristics: leading enterprises continue to excel, with three companies reporting revenues exceeding 10 billion yuan; the industrial structure is continuously optimized; R&D investment has significantly increased, with 2024 R&D expenses reaching 5.396 billion yuan, a year-on-year increase of 25.49% [11]. - There is a growing awareness of legal compliance and integrity, with 82 enterprises establishing legal risk control systems and 62 implementing bidding management systems [11]. - Social responsibility is actively pursued, with 51 enterprises participating in rural revitalization efforts, contributing to employment stability with an average of 1,738 jobs created per enterprise [11]. Group 3: Notable Companies - Zhongwei New Materials Co., Ltd. ranks first in the 2025 Guizhou Top 100 Private Enterprises, followed by Guizhou Tongyuan Group and Guizhou Geely Automobile Manufacturing Co., Ltd. [12][23]. - In the Top 20 Private Manufacturing Enterprises, Zhongwei New Materials Co., Ltd. also leads, followed by Guizhou Geely Automobile Manufacturing Co., Ltd. and Guiyang Hisense Electronics Co., Ltd. [23].

Group 1 - The Chinese medicine sector experienced a slight increase of 0.45% on December 18, with Yibai Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3876.37, up 0.16%, while the Shenzhen Component Index closed at 13053.98, down 1.29% [1] - Key stocks in the Chinese medicine sector showed varied performance, with Yibai Pharmaceutical closing at 4.29, up 5.67%, and other notable gainers including Jinhua Co. and Xinda Pharmaceutical [1] Group 2 - The Chinese medicine sector saw a net outflow of 362 million yuan from major funds, while retail investors contributed a net inflow of 384 million yuan [2] - Among the stocks, *ST Changyao experienced the largest decline, down 6.21% to 1.51, while Zhongsheng Pharmaceutical and Te Yi Pharmaceutical also faced losses [2] - The trading volume and turnover for various stocks in the sector varied significantly, with Zhongsheng Pharmaceutical recording a turnover of 910 million yuan despite a decline [2] Group 3 - Major funds showed a net inflow in stocks like Pianzi Shou and Lingrui Pharmaceutical, while retail investors had mixed results across different stocks [3] - The net inflow for Pianzi Shou was 22.60 million yuan, while other stocks like Guizhou Bailing and Taiji Group also saw notable fund movements [3] - The overall trend indicates a divergence in fund flows, with some stocks attracting significant retail interest despite overall sector outflows [3]

证券日报网讯 12月5日晚间，益佰制药发布公告称，中证天通会计师事务所（特殊普通合伙）（以下简 称"中证天通"）作为公司2025年度财务报表和内部控制的审计机构，原委派孙太宏担任公司2025年度财 务报表和内部控制审计报告的签字注册会计师，由于原第二签字注册会计师孙太宏已从中证天通离职， 现中证天通委派肖缨接替孙太宏作为公司第二签字注册会计师。变更后公司2025年度财务报表和内部控 制审计报告的签字注册会计师为李朝辉、肖缨，质量控制复核人为邵富霞。 （文章来源：证券日报） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：600594 证券简称：益佰制药 公告编号：2025-040 贵州益佰制药股份有限公司 关于年度审计机构变更签字注册会计师的公告 肖缨不存在违反《中国注册会计师职业道德守则》对独立性要求的情形， 最近三年未受（收）到任何刑事处罚、行政处罚、行政监管措施和自律监管措 施,具备相应专业能力和丰富的从业经验。 三、本次变更对公司的影响 贵州益佰制药股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开了第八届董事会第十一次会议，于 2025 年 5 月 16 日召开了 2024 年年度股东 大会，审议通过了《关于续聘公司 2025 年年度审计机构的议案》，同意续聘中 证天通会计师事务所（特殊普通合伙）（以下简称"中证天通"）为公司 2025 年年度财务报告及内部控制审计机构，具体内容详见公司于 2025 年 4 月 26 日 在上海证券交易所网站（www.sse.com.cn）披露的《贵州益佰制药股份有限公 司关于续聘公司 2025 年年度审计机构的公告》（ ...